Regal Assets Analytics

ADMA

ADMA New Catalysts For 2019 – Two PDUFA decisions on immunodeficiency therapies

By |2020-03-30T10:13:47-04:00January 22nd, 2019|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Probability Sentiment|Tags: , |

SUMMARY SanaCurrents assigns a pivotal sentiment the FDA will approve [...]

ADMA Biologics Believes It Can Resolve CRL Issues Quickly, Spring Review Possible

By |2018-12-28T10:31:02-05:00December 28th, 2018|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents|Tags: , , |

Shares of ADMA Biologics [NASDAQ:ADMA]  fell more than 45% on [...]

ADMA Biologics Receives a Split FDA Decision on BIVIGAM

By |2018-12-20T15:03:58-05:00December 20th, 2018|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents|Tags: , , |

ADMA Biologics (NASDAQ:ADMA), a company specializing in the manufacturing and development [...]